Natriuretic peptides: biochemical markers of anthracycline cardiac toxicity?
Patients with cancer are often treated with potentially cardiotoxic chemotherapeutics. Cardiotoxicity ranges from relatively benign arrhythmias to serious conditions such as myocardial ischemia/infarction, congestive heart failure, and cardiomyopathy. In spite of different diagnostic methods, with echocardiography as a gold standard, there is an intensive search for new diagnostic tools for the early detection of myocardial abnormalities. Available data suggest that the levels of circulating cardiomarkers can monitor the extent and severity of the myocardial damage. The role of routinely used cardiomarkers is controversial and limited in this setting. Natriuretic peptides have shown promising results in assessment and monitoring of both acute and late clinical and subclinical damage of the myocardium in association with chemotherapy. This article reviews clinical studies evaluating the role of natriuretic peptides in the early diagnosis of anthracycline cardiotoxicity, and their use in the management of cancer survivors.
Urbanova
D
D
Institute of Pathophysiology, Comenius University Medical School, Bratislava, Slovakia. dagmar.urbanova@fmed.uniba.sk
Urban
L
L
Danova
K
K
Simkova
I
I
D018943:Anthracyclines / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000378:metabolism*; D006321:Heart / Q000187:drug effects*; D006331:Heart Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism; D006801:Humans; D045265:Natriuretic Peptides / Q000378:metabolism*
D018943:Anthracyclines; D000970:Antineoplastic Agents; D015415:Biomarkers; D045265:Natriuretic Peptides